Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Uhi, Toh"'
Autor:
Rie Sugihara, Hidetaka Watanabe, Shuntaro Matsushima, Yuriko Katagiri, Shuko Saku, Mina Okabe, Yuko Takao, Nobutaka Iwakuma, Etsuyo Ogo, Fumihiko Fujita, Uhi Toh
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background The primary tumor resection (PTR) of de novo stage IV breast cancer (DnIV BC) is controversial, and previous studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) could be a poor-prognosis factor for BC. We investig
Externí odkaz:
https://doaj.org/article/da888d77f3f348358e3bf2fc77371236
Autor:
Mayumi Ono, Michihiko Kuwano, Masayoshi Kage, Maki Tanaka, Shigehiro Ohdo, Ken-ichi Ito, Uhi Toh, Ryuji Takahashi, Yuichi Murakami, Chihiro Fukumitsu, Satoshi Hattori, Akihiko Kawahara, Hiroto Izumi, Kosuke Watari, Tomohiro Shibata
Supplementary Figure S1. Effect of YBX1 on ESR protein expression and ubiquitination of ESR. Supplementary Figure S2. Effect of ESR knockdown on ERBB2 expression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fd69ee50e8d3d706e3892f4951f41bf
https://doi.org/10.1158/0008-5472.22414299.v1
https://doi.org/10.1158/0008-5472.22414299.v1
Autor:
Mayumi Ono, Michihiko Kuwano, Masayoshi Kage, Maki Tanaka, Shigehiro Ohdo, Ken-ichi Ito, Uhi Toh, Ryuji Takahashi, Yuichi Murakami, Chihiro Fukumitsu, Satoshi Hattori, Akihiko Kawahara, Hiroto Izumi, Kosuke Watari, Tomohiro Shibata
Endocrine therapies effectively improve the outcomes of patients with estrogen receptor (ER)-positive breast cancer. However, the emergence of drug-resistant tumors creates a core clinical challenge. In breast cancer cells rendered resistant to the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5aa7f556a1ee64bba60ee1acd9b47ffa
https://doi.org/10.1158/0008-5472.c.6508941.v1
https://doi.org/10.1158/0008-5472.c.6508941.v1
Autor:
Mayumi Ono, Michihiko Kuwano, Masayoshi Kage, Maki Tanaka, Shigehiro Ohdo, Ken-ichi Ito, Uhi Toh, Ryuji Takahashi, Yuichi Murakami, Chihiro Fukumitsu, Satoshi Hattori, Akihiko Kawahara, Hiroto Izumi, Kosuke Watari, Tomohiro Shibata
Supplementary Figure Legends and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b43f548860a1ac1941590abd0e68fcbb
https://doi.org/10.1158/0008-5472.22414302.v1
https://doi.org/10.1158/0008-5472.22414302.v1
Autor:
NANAE OGATA, UHI TOH, TOMOYA SUDOU, SUGURU OGATA, YUKO TAKAO, RIE SUGIHARA, HIDEAKI WATANABE, SHUNTARO MATUSHIMA, YOSHITO AKAGI
Publikováno v:
Anticancer research. 42(8)
Post-menopausal breast cancer (BC) patients who receive adjuvant aromatase inhibitor (AI) therapy may be at increased risk of bone loss, osteoporosis, and bone fracture. We aimed to evaluate the efficacy and safety of oral bisphosphonate minodronate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a86e3040a5ada05178360b9cd1f905c
https://pubmed.ncbi.nlm.nih.gov/35896231
https://pubmed.ncbi.nlm.nih.gov/35896231
Publikováno v:
Molecular and Clinical Oncology. 16
The present study aimed to clarify the humoral and cellular immune responses of patients with cancer who experienced no recurrence over a long term after receiving a cancer vaccine. The immune kinetics were investigated in response to a personalized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79590b40e98864c863fcd605f292bcad
https://doi.org/10.3892/mco.2022.2545
https://doi.org/10.3892/mco.2022.2545
Autor:
Hiroyasu Yamashiro, Koichiro Tsugawa, Kojiro Mashino, Tatsuya Toyama, Tomomi Fujisawa, Shoichiro Ohtani, Uhi Toh, Rikiya Nakamura, Masakazu Toi, Takahiro Nakayama, Naoto Kondo, Masahiro Kashiwaba, Shinji Ohno, Yutaka Yamamoto, Yuichi Tanino, Takashi Ishikawa, Hidetoshi Kawaguchi, Toshimi Takano, Masato Takahashi, Satoshi Morita
Publikováno v:
Breast Cancer (Tokyo, Japan)
Purpose To investigate the effectiveness and safety of bevacizumab–paclitaxel combination therapy as first- or second-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer in daily clinical practice. Methods In this prosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d22c2e16b3691a9cd84497d58bc292b0
https://doi.org/10.1007/s12282-020-01138-4
https://doi.org/10.1007/s12282-020-01138-4
Autor:
Takashi Kuwayama, Takahiro Nakayama, Manabu Futamura, Norikazu Masuda, Takanori Kin, Morihito Okada, Yutaka Mizuno, Akira Hirano, Takeshi Nagashima, Uhi Toh, Masafumi Inokuchi, Hiroyuki Yasojima, Mari S. Oba, Toshiaki Saeki, Hiroko Bando, Shinji Ohno, Yutaka Yamamoto, Kazuhiko Yamagami, Yasuyuki Kojima
Publikováno v:
Cancer Research. 80:P2-16
[Background] Nanoparticle albumin-bound paclitaxel (Nab-PTX) is a novel taxane formulation that was developed to avoid Cremophor/ethanol associated toxicities such as peripheral neuropathy and hypersensitive reactions. Since Taxol plays an important
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3648cfb0ba7c257d0b8c1ea620d6ffc
https://doi.org/10.1158/1538-7445.sabcs19-p2-16-13
https://doi.org/10.1158/1538-7445.sabcs19-p2-16-13
Autor:
Masakazu Toi, Hiroji Iwata, Tohru Ohtake, Naruto Taira, Masahiro Kashiwaba, Rikiya Nakamura, Tomomi Fujisawa, Yuichiro Kikawa, Masahiro Takada, Shinji Ohno, Yutaka Yamamoto, Satoshi Morita, Shigehira Saji, Yoshie Hasegawa, Tatsuya Toyama, Norikazu Masuda, Takanori Ishida, Masahiro Kitada, Uhi Toh, Toshimi Takano
Publikováno v:
Cancer Research. 80:P2-15
Background: The standard chemotherapy treatment strategy for patients with advanced/metastatic breast cancer (ABC) is the continuation of the same drug until tumor progression. However, despite continued antitumor effects, continuation of a drug ofte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcef45c997bf31cc015eea64a5b52c73
https://doi.org/10.1158/1538-7445.sabcs19-p2-15-01
https://doi.org/10.1158/1538-7445.sabcs19-p2-15-01
Autor:
Momoko Akashi, Hitoshi Obara, Hirohisa Yano, Rin Yamaguchi, Jun Akiba, Uhi Toh, Maki Tanaka, Miki Yamaguchi, Tatsuyuki Kakuma, Yoshito Akagi, Hironori Kusano
Publikováno v:
Histopathology. 76:560-571
AIMS HER2-positive (HER2+) breast carcinoma (BC) cases are often treated similarly; however, they can be classified as either luminal B (LH) or non-luminal type (NLH) BC, which have different prognoses. In this study, we investigated the clinicohisto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91f9b8f5950451b8132b7eba704ebe48
https://doi.org/10.1111/his.14003
https://doi.org/10.1111/his.14003